

**In the Specification:**

Please replace the paragraph beginning at page 1, line 26, with the following:

--This application is a continuation in part of the U.S. patent application Serial No. 10/040,862, filed November 6, 2001, Attorney Docket No. 014058-013520US, entitled COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES, which is a continuation in part of U.S. Serial No. 09/796,692 filed March 1, 2001, which claims priority to United States Provisional Patent Application Serial Nos. 60/186,126, filed March 1, 2000; Serial No. 60/190,479, filed March 17, 2000; Serial No. 60/200,545, filed April 27, 2000; Serial No. 60/200,303, filed April 28, 2000; Serial No. 60/200,779, filed April 28, 2000; Serial No. 60/200,999; filed May 1, 2000; Serial No. 60/202,084, filed May 4, 2000; Serial No. 60/206,201, filed May 22, 2000; Serial No. 60/218,950, filed July 14, 2000; Serial No. 60/222,903, filed August 3, 2000; Serial No. 60/223,416, filed August 4, 2000; and Serial No. 60/223,378, filed August 7, 2000; the entire specification, claims, sequences and figures of each of which is specifically incorporated herein by reference in its entirety without disclaimer and for all purposes.--

Please replace the paragraph beginning at page 1, line 26, with the following:

--The Sequence Listing written in file -144-0-2.APP, 6,764,544 bytes, created on July 18, 2002, on duplicate copies of compact disc of the written form of the Sequence Listing, *i.e.*, "Copy 1 of 3" and "Copy 2 of 3", and the sequence information recorded in computer readable form on compact disc, *i.e.*, "Copy 3 of 3" for Application No: 10/057,475, Gaiger *et al.*, COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES, is hereby incorporated by reference.--

Please replace the paragraph beginning at page 17, line 16, with the following:

--**FIGS. 5 and 6** illustrate the cDNAs that are highly expressed in lymphoma cells (SEQ ID NOs:10,486-10,536 and SEQ ID NOs:10,10,537-10,580, respectively);--

Please replace the paragraph beginning at page 17, line 22, with the following:

--**FIG. 9** lists the nucleotide sequences (SEQ ID NOs:10,581-10,596) of antigens with similar tissue expression profiles as CD20 and CD52;--

Please replace the paragraph beginning at page 17, line 25, with the following:

--**FIG. 10** lists the nucleotide and protein sequences of Ly1464 (SEQ ID NOs:10,597 and 10,598);--

Please replace the paragraph beginning at page 17, line 26, with the following:

--**FIG. 11** illustrates the results of the TMpred report for Ly1464 (SEQ ID NO:10,598);--

Please replace the paragraph beginning at page 17, line 27, with the following:

--**FIG. 12** lists the MHC Class binding peptides of Ly1464 (SEQ ID NOs:10,599-10,818);--

Please replace the paragraph beginning at page 17, line 28, with the following:

--**FIG. 13** illustrates the results of analyzing Ly1464 (SEQ ID NO:10,598) with the TSITES program;--

Please replace the paragraph beginning at page 17, line 29, with the following:

--**FIG. 14** lists the immunogenic peptides of Ly1464 (SEQ ID NOs:10,820-10,842);--

Please replace the paragraph beginning at page 17, line 31, with the following:

--**FIG. 15** illustrates the laboratory procedure used to synthesize recombinant Ra12-Ly1464 (cloning primers = SEQ ID NOs:10,843 and 10,844; 6x His tag = SEQ ID NO:10,979);--

Please replace the paragraph beginning at page 17, line 33, with the following:

--**FIG. 16** lists the Ly1464 nucleotide sequence (SEQ ID NO:10,845), the Ra12-Ly1464 nucleotide sequence (SEQ ID NO:10,467), the Ra12-Ly1464 amino acid sequence (SEQ ID NO:10,468), and the properties of the Ly1464 protein;--

Please replace the paragraph beginning at page 18, line 2, with the following:

--**FIG. 17** lists Ly1484 nucleotide (SEQ ID NO:10,846) and amino acid (SEQ ID NO:10,897 and 10,848) sequences;--

Please replace the paragraph beginning at page 18, line 3, with the following:

--**FIG. 18** illustrates the results of the TMpred report for Ly1484 long (SEQ ID NO:10,847) and Ly1484 short (SEQ ID NO:10,848);--

Please replace the paragraph beginning at page 18, line 5, with the following:

--**FIG. 19** lists the MHC class I binding peptides of Ly1484 long (SEQ ID NOs:10,849-10,908);--

Please replace the paragraph beginning at page 18, line 6, with the following:

--**FIG. 20** lists the MHC class I binding peptides of Ly1484 short (SEQ ID NOs:10,909-10,968);--

Please replace the paragraph beginning at page 18, line 7, with the following:

--**FIG. 21** illustrates the results of the TSITES analysis of Ly1484 long (SEQ ID NO:10,847);--

Please replace the paragraph beginning at page 18, line 8, with the following:

--**FIG. 22** illustrates the results of the TSITES analysis of Ly1484 short (SEQ ID NO:10,848);--

Please replace the paragraph beginning at page 18, line 12, with the following:

--**FIG. 24** lists the sequence of GenBank clone on chromosome 15q21 clone b2265b18 (acc. no. AC008131) (SEQ ID NO:10,475), a clone that matches with Ly1485P.--

Please replace the paragraph beginning at page 18, line 14, with the following:

--**FIG. 25** lists the sequence of the human secreted protein-encoding gene 9 cDNA clone HTOHB55 SEQ ID NO:1 (acc. no. AAH19210) (SEQ ID NO:10,476), a clone that matches with Ly1485P.--

Please replace the paragraph beginning at page 18, line 16, with the following:

--**FIG. 26** lists the sequence of human secreted protein-encoding gene 9 cDNA clone HTOHB55 SEQ ID NO:19 (acc. no. AAH19178) (SEQ ID NO:10,477) on chromosome 15q21, a clone that matches with Ly1485P.--

Please replace the paragraph beginning at page 18, line 20, with the following:

--**FIG. 27** lists the nucleotide (SEQ ID NO:10,970) and amino acid (SEQ ID NO:10,969) sequences of Ly1488;--

Please replace the paragraph beginning at page 18, line 21, with the following:

--**FIG. 28** illustrates the results of the TMpred analysis of Ly1488 (SEQ ID NO:10,969);--

Please replace the paragraph beginning at page 18, line 23, with the following:

--**FIG. 29** lists the nucleotide sequence for the lung cancer associated polynucleotide sequence SQID 265 (Genseq accession number AAF18246) (SEQ ID NO:10,478), a clone that matches the Ly1449 and Ly1480 sequences.--

Please replace the paragraph beginning at page 18, line 26, with the following:

--**FIG. 30** lists the nucleotide sequence for the *Homo sapiens* GenBank clone on chromosome 17 clone RP11-956N15 (accession number AC021581) (SEQ ID NO:10,479), a clone that matches the Ly1449 and Ly1480 sequences.--

Please replace the paragraph beginning at page 140, line 27, with the following:

--Analysis of hematological malignancy subtracted clones by microarray analyses on a variety of microarray chips identified the sequences set forth in SEQ ID NO:1 through SEQ ID NO:664 of the instant application and co-pending application USSN 09/796,692 as being at least two-fold overexpressed in hematological malignancies versus normal tissues.--

Please replace the paragraph beginning at page 141, line 4, with the following:

--Table 7 in co-pending application USSN 09/796,692 lists the sequences of the polynucleotides obtained during the analyses of the present invention. Shown are the 664 polynucleotide sequences, along with their clone name identifiers, as well as the serial number and filing date of the priority provisional patent application in which the clone was first identified. Also listed in Table 7 are the TCL-I DNA and protein (SEQ ID NOs:665 and 666) and Coronin1A DNA and protein (SEQ ID NOs:667 and 668).--

Please replace the paragraph beginning at page 141, line 9, with the following:

--Table 8 in co-pending application USSN 09/796,692 identifies the putative open reading frames obtained from analyses of the cDNA sequences obtained in SEQ ID NO:1-SEQ ID NO:664 in the co-pending application. Shown are the sequence identifiers, the clone name and translation frame, and the start and stop nucleotides in the

corresponding DNA sequence used to generate the polypeptide sequence of the open reading frame (SEQ ID NOs:669-2532).--

Please replace the paragraph beginning at page 141, line 14, with the following:

--Table 9 in co-pending application USSN 09/796,692 identifies an additional set of particular hematological malignancy-related cDNA sequences that were obtained using the subtractive library and microarray methods as described above. These sequences, designated SEQ ID NO:2533-SEQ ID NO:9597 in the instant application and co-pending application USSN 09/796,692, are shown in the Table along with the original clone name, and the serial number and filing date of the priority provisional application in which the clone was first described.--

Please replace the paragraph beginning at page 145, line 30, with the following:

--A full length sequence of candidate Ly1484P (Figure 17) was obtained using the Genbank database. Ly1484P was mapped to human chromosome 10. There is both a long and short version of Ly1484P (Figure 17; long version – SEQ ID NO:10,847; short version – SEQ ID NO:10,848). TMpred analysis of Ly1484P indicates that this protein contains a transmembrane domain (Figure 18). Several MHC class I binding peptides of Ly1484P have been identified (Figures 19 & 20; SEQ ID NOs:10,849-10,908 and 10,909-10,968, respectively) and are being used to generate antigen-specific CTLs. Using the TSITES program, T-helper epitopes have also been identified (Figures 21 & 22). Polypeptides have been generated and are being used to generate antibodies that are specific for Ly1484P.--

Please replace the paragraph beginning at page 149, line 23, with the following:

--SEQ ID NO:9599 in the instant application and co-pending application USSN 10/040,862, also termed "Ly1448," a portion of which was disclosed earlier in co-pending application USSN 09/796,692 as SEQ ID NO:636 was used to screen a series of MicroArray and RealTime chips and panels containing cDNAs made from RNAs isolated from normal cells and hematologically malignant cells. SEQ ID NO:9599 appeared to be expressed in normal B cell lines, CD 19<sup>+</sup> cell lines, and highly expressed in a subset of Non-Hodgkins B-cell lymphoma cell lines, Hodgkins lymphoma cell lines, follicular lymphoma cell lines, and Chronic Lymphocytic Leukemia cell lines.--

Please insert the accompanying Sequence Listing submitted on compact disc in triplicate in accordance with 37 C.F.R. §1.821(c).

**In the Informal Sequence Listing:**

Please replace the paragraph beginning at page 186, line 48 with the following:

**--SEQ ID NO:10,482: Ly1452 with His tag nucleotide sequence (see, Example 13)--**

Please replace the paragraph beginning at page 187, line 32 with the following:

**--SEQ ID NO:10,483: Ly1452 with His tag amino acid sequence (see, Example 13)--**

Please replace the paragraph beginning at page 209, line 24 with the following:

**--SEQ ID NO: 10,598 - Ly1464 protein sequence**

see, Figure 10, Figure 11 and Figure 13--